Bio-FD&C Co Ltd
KOSDAQ:251120
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (7.4), the stock would be worth ₩16 434.48 (15% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.5 | ₩14 310 |
0%
|
| 3-Year Average | 7.4 | ₩16 434.48 |
+15%
|
| 5-Year Average | 7.8 | ₩17 227.64 |
+20%
|
| Industry Average | 17.7 | ₩38 990.41 |
+172%
|
| Country Average | 1 | ₩2 313.47 |
-84%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
₩133.1B
|
/ |
Oct 2025
₩18.8B
|
= |
|
|
₩133.1B
|
/ |
Dec 2025
₩18.5B
|
= |
|
|
₩133.1B
|
/ |
Dec 2026
₩22.6B
|
= |
|
|
₩133.1B
|
/ |
Dec 2027
₩27.2B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
B
|
Bio-FD&C Co Ltd
KOSDAQ:251120
|
122B KRW | 6.5 | 17.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 6.1 | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 5.1 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 5.5 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 9 | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 5.2 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 2.7 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.5 |
| Median | 1 |
| 70th Percentile | 2.4 |
| Max | 101 134.7 |
Other Multiples
Bio-FD&C Co Ltd
Glance View
Bio-FD&C Co., Ltd. engages in the development of bio and health technologies. The company is headquartered in Incheon, Incheon and currently employs 61 full-time employees. The company went IPO on 2022-02-21. The firm is mainly engaged in the manufacture and sale of soybean callus culture extract, clock stem cell, centella asiatica, callus extract, aloe barbadensis phytoplaceta extract, prunus mume phytoplacenta extract, secale cereale adventitious root extract, acanthopanax koreanum adventitious root culture extract. The firm's products are mainly used as materials for cosmeceuticals, health functional foods and pharmaceuticals.
